Cargando…

Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis

BACKGROUND: Assessing Mycobacterium tuberculosis (TB) viability by fluorescein diacetate (FDA) microscopy can predict TB culture results, treatment response and infectiousness. However, diverse methods have been published. We aimed to optimise FDA microscopy, minimising sputum processing, biohazard...

Descripción completa

Detalles Bibliográficos
Autores principales: Datta, Sumona, Alvarado, Keren, Gilman, Robert H., Valencia, Teresa, Aparicio, Christian, Ramos, Eric S., Montoya, Rosario, Evans, Carlton A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490897/
https://www.ncbi.nlm.nih.gov/pubmed/31039160
http://dx.doi.org/10.1371/journal.pone.0214131
_version_ 1783414897622646784
author Datta, Sumona
Alvarado, Keren
Gilman, Robert H.
Valencia, Teresa
Aparicio, Christian
Ramos, Eric S.
Montoya, Rosario
Evans, Carlton A.
author_facet Datta, Sumona
Alvarado, Keren
Gilman, Robert H.
Valencia, Teresa
Aparicio, Christian
Ramos, Eric S.
Montoya, Rosario
Evans, Carlton A.
author_sort Datta, Sumona
collection PubMed
description BACKGROUND: Assessing Mycobacterium tuberculosis (TB) viability by fluorescein diacetate (FDA) microscopy can predict TB culture results, treatment response and infectiousness. However, diverse methods have been published. We aimed to optimise FDA microscopy, minimising sputum processing, biohazard and complexity for use in resource-constrained settings. METHODS AND RESULTS: Optimization: Patients with smear-positive pulmonary TB before treatment and healthy control participants provided sputa. These were divided into equal aliquots that were tested directly or after NaOH centrifuge-decontamination. Each aliquot was cultured and used to prepare slides (n = 80). FDA microscopy used: 1 or 3 drops of sputum; with/out acid-alcohol wash; with/out phenol sterilization; with 0/30/60 seconds KMnO(4) quenching. Control samples all had negative culture and microscopy results. FDA microscopy had higher sensitivity when performed directly (without centrifuge-decontamination) on 1 drop of sputum (P<0.001), because 3 drops obscured microscopy. Acid-alcohol wash and KMnO(4) quenching made bacilli easier to identity (P = 0.005). Phenol sterilization did not impair microscopy (P>0.1). Validation: The 2 protocols that performed best in the optimization experiments were reassessed operationally by comparing duplicate slides (n = 412) stained with KMnO(4) quenching for 30 versus 60 seconds. FDA microscopy results were similar (P = 0.4) and highly reproducible, with 97% of counts agreeing within +/-1 logarithm. Storage: Smear microscopy slides and aliquots of the sputum from which they were made were stored for 4 weeks. Twice-weekly, paired slides (n = 80) were stained with freshly prepared versus stored FDA and read quantitatively. Storing sputum, microscopy slides or FDA solution at 4°C or room temperature had no effect on FDA microscopy results (all P>0.2). Cost: Material costs for each slide tested by FDA microscopy using reagents purchased locally were USD $0.05 and required the same equipment, time and skills as auramine acid-fast microscopy. CONCLUSIONS: We recommend a simple, bio-secure protocol for FDA microscopy that provides sensitive and repeatable results without requiring centrifugation.
format Online
Article
Text
id pubmed-6490897
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64908972019-05-17 Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis Datta, Sumona Alvarado, Keren Gilman, Robert H. Valencia, Teresa Aparicio, Christian Ramos, Eric S. Montoya, Rosario Evans, Carlton A. PLoS One Research Article BACKGROUND: Assessing Mycobacterium tuberculosis (TB) viability by fluorescein diacetate (FDA) microscopy can predict TB culture results, treatment response and infectiousness. However, diverse methods have been published. We aimed to optimise FDA microscopy, minimising sputum processing, biohazard and complexity for use in resource-constrained settings. METHODS AND RESULTS: Optimization: Patients with smear-positive pulmonary TB before treatment and healthy control participants provided sputa. These were divided into equal aliquots that were tested directly or after NaOH centrifuge-decontamination. Each aliquot was cultured and used to prepare slides (n = 80). FDA microscopy used: 1 or 3 drops of sputum; with/out acid-alcohol wash; with/out phenol sterilization; with 0/30/60 seconds KMnO(4) quenching. Control samples all had negative culture and microscopy results. FDA microscopy had higher sensitivity when performed directly (without centrifuge-decontamination) on 1 drop of sputum (P<0.001), because 3 drops obscured microscopy. Acid-alcohol wash and KMnO(4) quenching made bacilli easier to identity (P = 0.005). Phenol sterilization did not impair microscopy (P>0.1). Validation: The 2 protocols that performed best in the optimization experiments were reassessed operationally by comparing duplicate slides (n = 412) stained with KMnO(4) quenching for 30 versus 60 seconds. FDA microscopy results were similar (P = 0.4) and highly reproducible, with 97% of counts agreeing within +/-1 logarithm. Storage: Smear microscopy slides and aliquots of the sputum from which they were made were stored for 4 weeks. Twice-weekly, paired slides (n = 80) were stained with freshly prepared versus stored FDA and read quantitatively. Storing sputum, microscopy slides or FDA solution at 4°C or room temperature had no effect on FDA microscopy results (all P>0.2). Cost: Material costs for each slide tested by FDA microscopy using reagents purchased locally were USD $0.05 and required the same equipment, time and skills as auramine acid-fast microscopy. CONCLUSIONS: We recommend a simple, bio-secure protocol for FDA microscopy that provides sensitive and repeatable results without requiring centrifugation. Public Library of Science 2019-04-30 /pmc/articles/PMC6490897/ /pubmed/31039160 http://dx.doi.org/10.1371/journal.pone.0214131 Text en © 2019 Datta et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Datta, Sumona
Alvarado, Keren
Gilman, Robert H.
Valencia, Teresa
Aparicio, Christian
Ramos, Eric S.
Montoya, Rosario
Evans, Carlton A.
Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
title Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
title_full Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
title_fullStr Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
title_full_unstemmed Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
title_short Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
title_sort optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490897/
https://www.ncbi.nlm.nih.gov/pubmed/31039160
http://dx.doi.org/10.1371/journal.pone.0214131
work_keys_str_mv AT dattasumona optimisingfluoresceindiacetatesputumsmearmicroscopyforassessingpatientswithpulmonarytuberculosis
AT alvaradokeren optimisingfluoresceindiacetatesputumsmearmicroscopyforassessingpatientswithpulmonarytuberculosis
AT gilmanroberth optimisingfluoresceindiacetatesputumsmearmicroscopyforassessingpatientswithpulmonarytuberculosis
AT valenciateresa optimisingfluoresceindiacetatesputumsmearmicroscopyforassessingpatientswithpulmonarytuberculosis
AT apariciochristian optimisingfluoresceindiacetatesputumsmearmicroscopyforassessingpatientswithpulmonarytuberculosis
AT ramoserics optimisingfluoresceindiacetatesputumsmearmicroscopyforassessingpatientswithpulmonarytuberculosis
AT montoyarosario optimisingfluoresceindiacetatesputumsmearmicroscopyforassessingpatientswithpulmonarytuberculosis
AT evanscarltona optimisingfluoresceindiacetatesputumsmearmicroscopyforassessingpatientswithpulmonarytuberculosis